

# Clinical Policy: Pramlintide (Symlin)

Reference Number: PA.CP.PST.13

Effective Date: 01/18

Last Review Date: 05/17

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

## Description

Pramlintide (Symlin<sup>®</sup>) is an amylin analog.

## FDA approved indication

Symlin is indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy.

## Policy/Criteria

Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria

It is the policy of Pennsylvania Health and Wellness<sup>®</sup> that Symlin is **medically necessary** when the following criteria are met:

### I. Initial Approval Criteria

#### A. Electronic Step Therapy for Symlin (must meet all):

1. Previous use of mealtime insulin therapy (e.g., Apidra, Humalog, Humulin, Novolin, Novolog, Relion) or an insulin pump in the last 30 days;
2. Dose does not exceed 120 mcg per injection (1 pen per injection).

**Approval duration: 6 months**

### II. Continued Therapy

#### A. Electronic Step Therapy for Symlin (must meet all):

1. Currently receiving medication via Pennsylvania Health and Wellness benefit or member has previously met initial approval criteria; or the Continuity of Care policy (PA.LTSS.PHAR.01) applies;
2. Current use of mealtime insulin therapy or an insulin pump;
3. If request is for a dose increase, new dose does not exceed 120 mcg per injection (1 pen per injection).

**Approval duration: 6 months**

### III. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

### IV. Dosage and Administration

Drug	Dosing Regimen	Maximum Dose
Symlin	1 injection subcutaneously prior to each major meal (≥ 250 kcal or containing ≥ 30 g of carbohydrate)	120 mcg/injection

**V. Product Availability**

- 1.5 mL SymlinPen disposable multidose pen-injector: 15 mcg, 30 mcg, 45 mcg, 60 mcg
- 2.7 mL SymlinPen disposable multidose pen-injector: 60 mcg, 120 mcg

**VI. References**

1. Symlin Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2015. Available at: [www.symmlin.com](http://www.symmlin.com). Accessed January 11, 2017.
2. American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017; 40(suppl 1): S1-S133.